• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Spectrum Solutions Collaborates with UCLA School of Dentistry

    Kwivik Therapeutics, EirMed Partner to Accelerate Product Commercialization

    Europe Marks its First Successful Remote Robotic-Assisted Coronary Angioplasty

    Twist on Heart Valve Design Boosts Blood Flow, Prevents Clots

    FDA Clears 3D Acellular Dermal Matrix
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Fixing Face Mask Form and Function

    The Heart of the Matter: Trends in Cardiology

    Virtually the Same? The Challenges of Online Conferences

    Digital Health Delivers During a Year for the Ages

    Advanced Technology for Staking and Swaging Medical Plastics
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    PTI Engineered Plastics Inc.

    Creganna Medical, part of TE Connectivity

    Element

    Qosina Corp.

    FUTEK Advanced Sensor Technology Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Meeting Critical Ventilator Product Requirements Amid Pandemic

    Impact of COVID-19 on the Medtech Supply Chain

    Finding the Upside to a Challenging Year

    Preparing Your Design Controls for FDA Approval

    A 'Trial and Error' Approach to Micromolded Parts
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Creganna Medical, part of TE Connectivity

    K-Tube Technologies

    maxon

    Concise Engineering

    Unicep
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Features

    Diagnostic Dexterity: Examining the IVD Industry

    In vitro diagnostic testing technology aims to become more user friendly and issue faster results to patients.

    Diagnostic Dexterity: Examining the IVD Industry
    The BD Veritor is a small, point-of-care device for determining if someone has the flu. All images courtesy of BD.
    Diagnostic Dexterity: Examining the IVD Industry
    The BD Kiestra is a modular lab automation platform.
    Related CONTENT
    • Freudenberg Medical Expands Injection Molding Operations
    • FDA OKs Hologic's Aptima HIV-1 Quant Dx Assay for HIV Diagnosis
    • QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test
    • ArchiMed Acquires Majority Interest in NAMSA
    • MPO Summit Conference Program Notebook
    Sam Brusco, Associate Editor11.07.17
    For a very long time, the surgical biopsy—a sample of tissue taken from the body for examination—has been the diagnostic standard. Biopsies are most commonly done to look for cancer after tissue abnormalities are discovered—for example, if an ultrasound or MRI reveals a lump or mass, or a mole on the skin has changed shape. Nearly all of these involve using a sharp tool to remove the tissue in question. They can be CT-guided to minimize discomfort, but are always invasive to some degree.

    As a result of medicine’s push toward minimally invasive procedures, an alternative, far less painful biopsy method has emerged. Liquid biopsy enables doctors to discover a wealth of information about a tumor through a blood sample (i.e., liquid), rather than a surgical procedure. Fragments of DNA deposited into the bloodstream by tumors have shown success in non-invasive screening for early-stage cancers, monitoring cancer treatment response, and explaining why some cancers resist therapies.

    “Procedures of the traditional tissue biopsy are painful, associated with complications such as potential infections, and often available only in central hospitals which require patients to travel long distances,” former MIT postdoc Mohammad Qasaimeh, who was involved in a study in which a microfluidic technique was used to capture and count circulating plasma cells from small samples of blood to diagnose and track multiple myeloma progression, said in a press release. “Capturing plasma cells from blood samples can serve as a liquid biopsy, which can be performed in clinics as often as required, and serve as a diagnostic and prognostic test during and after chemotherapy treatment. Moreover, captured cells can be used for drug testing and thus serve as a tool for personalized medicine.”

    This in vitro diagnostic (IVD) method has the potential to transform cancer care, but it’s still relatively early in development. Taking and testing tissue samples still remains the standard, and a number of questions would need to be addressed in clinical trials before making liquid biopsy common practice: How much does test accuracy vary among tumor types and cancer stages? Is the sampling representative of all the genetic clones in a tumor, or is there bias toward particular sub-regions? Until these are answered, liquid biopsy will remain in the clinical research stage.

    Established IVD technologies and devices are implemented in either clinical or over-the-counter environments to examine biological samples like blood, saliva, urine, or tissue collected from the body. These devices include chemicals and reagents, analytical equipment, disposables (cartridges or test strips), and software supporting the analytical processes in the lab.

    “In the IVD industry, there is growing interest in increasing the portfolio of complete clinical solutions,” illuminated Mario Koksch M.D., Ph.D., MBA, vice president and general manager, Flow Cytometry Business Unit of Indianapolis, Ind.-based Beckman Coulter Life Sciences, part of Danaher Corporation. Dr. Koksch is responsible for the global flow cytometry business, strategy, and manufacturing centers in Marseille, France; Bangalore, India; and Suzhou, China. “A complete clinical solution includes reagents, controls, calibrators, an automated sample prep, and automated data analysis approach. These complete solutions allow for higher quality results in a broader range of labs in less time, which makes initial diagnostics of disease states, monitoring the disease’s progress, and selecting the most appropriate treatment options for individual patients more straightforward, rational, and objective.”

    The IVD market is currently undergoing a transformation. Large instruments in central labs are seeing migration to tabletop and hand-held devices, particularly in areas like next-generation sequencing, molecular diagnostics, and point-of-care (PoC). IVD testing has been migrating from the hospital to the physician’s office, and in some cases, to the home. This trend has resulted in a degree of industry consolidation, evidenced by a few significant mergers and acquisitions over the past year. There is also strong pressure to control costs because reimbursement can be challenging for IVD technologies. Because of this and other factors, IVD labs must be incredibly efficient to keep costs down.

    “We see a number of increasing challenges facing IVD laboratories,” commented Christine Snyder, senior director of strategic marketing for Diagnostic Systems at Becton, Dickinson and Company (BD), a Franklin Lakes, N.J.-based firm that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. “The changing reimbursement landscape, shortage of qualified laboratory technologists, and ongoing consolidation of laboratories means larger organizations are serving more customers with fewer employees. With that, our customers continue to focus on providing fast and accurate test results with greater efficiency, which means we are seeing the widespread adoption of laboratory automation and informatics platforms, products and services. Increasing use of informatics technology helps our customers better manage laboratory information flow and can improve communication between laboratories and physicians.”

    Instant Interpretation
    The modern world craves immediate results. The medical extension of this need is realized in the impetus for technology to diagnose diseases at the PoC, rather than using traditional lab-based tests. PoC IVD devices fit the bill for this fast-paced attitude because they are usually portable, relatively simple to operate, and the instruments return results rapidly.

    Lab-based tests require an order to draw blood, followed by the patient’s trip to the draw site. The specimen is then sent for analysis to the lab, after which the result is finally communicated to the clinician, then finally to the patient or caregiver. Despite labs’ attempts to minimize this turnaround time, it can sometimes take a day or more to receive results. PoC diagnostic systems shortcut the steps of collecting and shipping a specimen; test results can be achieved on the spot in the doctor’s office or at home.

    “In the past, in vitro diagnostics were only available in the clinical setting,” recalled Ted Rowan, regional sales manager of Boyd Technologies, a Lee, Mass.-based international supplier and precision converter of advanced flexible materials for the medical device and life sciences markets. “Advances in technology have made it possible to take many tests at home, often with nearly instant results. Home tests are no less accurate, more convenient, and easily performed by the end user. PoC systems are generally membrane-based test strips enclosed inside a plastic cassette. These patient self-tests can detect changes in disease pathophysiology at the earliest onset, empowering patients to take better control of their illnesses.”

    “Existing and startup companies manufacturing PoC instruments and kits are advancing and growing rapidly,” observed Craig Occhiato, microfluidics team manager for Bürkert Fluid Control Systems, a Charlotte, N.C.-based manufacturer of measurement and control systems for liquids and gases for the medical device industry. “This is changing the convenience, time, and cost of the IVD landscape—moving it from the large lab and hospital lab to a doctor’s office, patient room, emergency medicine setting, or even a third world country.”

    PoC diagnostic technologies generally fall into two categories. The first are small handheld devices with accompanying test strips or cartridges that offer qualitative or quantitative analysis, for example a glucose biosensor fingerstick or a small cartridge device for blood gas analysis. Larger bench-top PoC devices are essentially smaller, less complex versions of laboratory instruments, for example critical care analyzers or small hematology and immunology analyzers.

    “When ITL first began work in the field over 40 years ago, most assays were being done in 96-well microplates, which by their very nature had a large footprint and required equally large processing stations,” recounted Tom Ackrill, business development manager of ITL Group, an Ashford, U.K.-based full-service subcontract company in the medical and diagnostic sector providing in vitro diagnostics, point-of-care devices, cancer staging and treatment, surgical robots, and next-generation DNA sequencing. (The company also has a growing presence stateside in Virginia.) “Modern technology has seen assays move from this format down onto single sample chips, and then gradually seems to be moving back towards multiplex assays—multiple tests being performed on a single sample to get the most ‘bang for your buck’ from a single droplet of blood, serum, urine, etc. This, combined with new focus areas such as next-generation sequencing (NGS), antimicrobial stewardship, and a re-emergence of infectious diseases such as Ebola or Plague—plus the nature of caring for an aging population—is pushing toward more rapid bedside tests.”

    Speedy diagnostics aren’t just a reaction to society’s collective impatience, however. As Ackrill mentioned, technologies for prompt diagnosis are crucial in order to respond to antimicrobial resistance (AMR) and troublesome emerging infectious diseases. More and more clinicians are encountering pathogen resistance to antibiotic therapies, and these must be diagnosed nearly instantly to protect patients. As is the case with most any blood-borne disease (but more urgent with those like Ebola or Plague) the sooner the diagnosis, the more effective the treatment will be. Firms developing IVD equipment understand this urgency, and constantly push to lower the turnaround time from test to actionable results.

    “In infectious disease diagnostics, the ability to deliver clinically actionable information rapidly is critical,” explained Snyder. “Specifically, the rapid identification of infection-causing pathogens directly from patient specimens—rather than from more time-consuming pathogen culturing methods—is an active area of innovation. Similarly, antimicrobial susceptibility testing is a time bottleneck ripe for disruptive innovation. Application of faster and cheaper NGS technology to identify pathogen drug resistance is an area of active development to address this bottleneck.”

    “To allow for earlier and more effective therapeutic intervention for infections, many emerging companies are actively developing molecular diagnostic PoC devices that allow for CLIA-waived clinical sample processing and rapid high sensitivity target detection,” Snyder continued. “And as AMR continues to be a pressing unmet clinical dilemma, host immune system status and mobilization is beginning to be recognized as a fertile area of translational research that may lead to novel diagnostic tests to predict infection outcomes—especially in the management of sepsis.”

    Go with the Flow
    The Coulter principle states that particles pulled through an orifice (concurrent with an electric current) create an impedance change proportional to the volume of the particle traveling through the orifice. The “pulse” in impedance arises from electrolyte displacement caused by the particle. A “Coulter counter” is an apparatus to count and size particles suspended in electrolytes, and has found significant commercial success in hematology to count and size cells making up whole blood. Flow cytometry has its roots in the Coulter principle and is engaged in order to count and sort cells, detect biomarkers, and engineer proteins. In the clinical environment, a flow cytometer is routinely used to diagnosis health disorders, particularly blood cancers.

    In case anyone is curious about the sudden science lesson, the patent for the first impedance-based flow cytometer (then called the Coulter counter) was issued to Wallace H. Coulter, who together with his brother Joseph founded Coulter Corporation in 1953. Coulter Corporation was acquired by Beckman Instruments in 1997, establishing Beckman Coulter Inc. (which itself is comprised of two businesses, Life Sciences and Diagnostics, and both divisions reside under Danaher). Among other offerings, the Beckman Coulter Life Sciences business is a manufacturer of clinical and research flow instruments.

    “The flow cytometry business continues a strong focus on expanding our offering of clinical products and services,” explained Koksch. “Cellular flow assays are providing very relevant and complementary information to molecular diagnostics assays, routine lab tests, and imaging methods. The advantages of flow assays include a rapid turnaround time, multiplexing capabilities to get more information from our small and precious samples, and analysis of functional cell information.”

    Flow cytometry has certainly come a long way since Wallace Coulter’s initial system—modern flow cytometers can analyze thousands of particles a second in real-time. They can also be configured as cell sorters by linking the cytometer’s analytical capability to a sorting device. This enables active separation and isolation of particles with specified optical parameters on a cell-by-cell basis.

    Flow cytometry has also become more widely utilized in clinical trials as well as research. New reagents for applications in drug discovery and diagnostics continue to be developed, and the rising prevalence of AIDS and cancer has provoked flow cytometry’s use in scientific research. The technology has even been used to support stem cell research.

    “Historically, flow cytometric methods had been widely used to add valuable cellular information to diagnostics and monitoring of treatment approaches for patients suffering from HIV and leukemia and lymphoma, including stem cell transplantations,” Koksch added. “In recent years, we recognize a growing interest in the use of flow methods to assess various aspects of the immune system in the context of cancer, infectious, and autoimmune diseases. While the current focus for these disease states is still on trials and clinical research studies to prove the clinical utility of potential new clinical assays, published results from various studies are very promising.”

    Market Prognosis
    According to a 2017 EvaluateMedTech report, worldwide IVD sales are expected to reach $70 billion by 2022. The market was valued at about $60.5 billion in 2016, according to the American Association for Clinical Chemistry (AACC). Medical device companies have been paying close attention to the market, and several large, recent M&A transactions have fortified their IVD portfolios. Danaher Corporation completed its $4 billion purchase of Cepheid in late 2016, adding a suite of easy-to-use molecular diagnostic systems and tests, including Cepheid’s GeneXpert systems for rapid genetic testing. Abbott Laboratories also closed its $5.3 billion acquisition of Alere in early October after over 18 months of tumultuous negotiations, adding a portfolio of rapid, PoC tests to the company’s already healthy diagnostic offerings. Despite some volatility in the industry due to changing IVD testing paradigms and reimbursement constraints, companies already established in IVD foresee the market to blossom as patients seek solutions for earlier, more rapid diagnosis.

    “We expect the market to continue advancing in technologies that speed the process of identifying diseases and the drugs they are susceptible to,” predicted Snyder. “Customers will seek companies that can provide more holistic solutions for rapidly detecting and monitoring infectious pathogens, where they will have multiple platforms to follow a patient from screening through definitive diagnosis and susceptibility testing.”

    The rise of personalized IVD instruments puts a great deal of pressure on suppliers servicing the industry as well. IVD manufacturers actively seek support for new product introductions from their supply chain partners. OEMs will continue to rely on their partners for expertise in areas such as fluid handling and processing, as well as medical material selection.

    “With IVD suppliers shipping their products globally, we anticipate suppliers will be required to support their products locally,” stated Colin Rademacher, area sales manager, microfluidics for Bürkert Fluid Control Systems. “OEMs want to work with suppliers who speak the local language and support the products in a region with local support, if need be.”

    “As the cost for the new instruments reduces, the trend will keep shifting to the genomic-based personalized IVD instruments,” added Occhiato. “Advancements in handling the large amount of data fuels this trend. We will continue to meet challenges in the fluid handling and processing.”

    Further, the continued drive to develop a complete IVD solution will most likely require some degree of customization, particularly in the development of technologies like PoC cartridges. Specialized designers and engineers must have the knowledge in assay development, microfluidics, and systems engineering in order to develop a product from top to bottom. (For more information on this, read “Designing Diagnostic Consumables: Custom or Off-the-Shelf?” a column featured in last month’s issue of MPO.)

    “In the IVD industry, there are literally no ‘one-size-fits-all’ solutions,” said Rowan. “Each and every device and test is required to meet different and specific criteria. Every material ranging from a particular reagent solution to filtration and membranous collection materials must be produced according to the testing device to achieve the best performance and most accurate and reliable results. The degree of customization needed in the supply chain to meet industry standards can be challenging. The supply chain plays a significant role in ensuring IVD product manufacturing is conducted without interruption. Companies with expertise in production of specific, varied, and custom microporous membranes are positioned for continued growth due to their agility.”

    The flow cytometry market is also expected to grow due to medical and technological advancements in cytometry products, as well as the aforementioned new reagents and cytometry’s adoption in the research landscape. According to Future Market Insights, the segment is expected to reach a high market valuation of $1.8 billion by 2022, with a CAGR of 7.2 percent. Cytometry’s proliferation will also benefit from IVD testing’s shift from traditional laboratories to clinics.

    “Flow cytometry as an example of a rapidly evolving IVD technology will serve the need of ease of use, supporting the migration of testing from highly specialized labs to routine clinical testing laboratories and getting diagnostics closer to our patients,” forecasted Koksch. “Overall, the IVD market will gradually evolve from a ‘detect when broken’ to a ‘monitor and prevent’ usage of new IVD solutions.”

    According to the AACC, the specific IVD areas of noninvasive prenatal testing, next-generation sequencing, liquid biopsy, and circulating tumor cell (CTC) tests are predicted to explode in the next five years. Statistics from Kalorama Information support this trend—the firm projects NGS test sales to grow from $250 million to $800 million, and CTC tests to rise from 100 million to 300 million. However, the firm also predicts a slowdown in the IVD industry as compared to the previous decade. The industry has previously grown at a pace of 5 percent to 6 percent according to Kalorama, and may slow to about 4 percent each year.

    “Patients are starting to expect benefits from all the investments seen over the years and public news stories about technologies promising sci-fi levels of innovation within the next few years,” concluded Ackrill. “Biomarkers also have the potential to play a big role moving forward—ELISA will probably still remain as a dominant force (even if it is antiquated technology) because it is fast, cheap, and effective. The market moving forward will probably involve the handling of more data (and more patient-specific data at that), which then brings the challenges of how to handle, store, and manage that information safely.” 
    Related Searches
    • cepheid
    • minimally invasive
    • biosensor
    • antimicrobial
    Related Knowledge Center
    • Diagnostics
    Suggested For You
    Freudenberg Medical Expands Injection Molding Operations Freudenberg Medical Expands Injection Molding Operations
    FDA OKs Hologic FDA OKs Hologic's Aptima HIV-1 Quant Dx Assay for HIV Diagnosis
    QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test
    ArchiMed Acquires Majority Interest in NAMSA ArchiMed Acquires Majority Interest in NAMSA
    MPO Summit Conference Program Notebook MPO Summit Conference Program Notebook
    Liquid Biopsy Could Detect Liver Cancer Earlier & Easier Liquid Biopsy Could Detect Liver Cancer Earlier & Easier
    New DuraClone RE Antibody Panels Are a Milestone in Rare Event Detection New DuraClone RE Antibody Panels Are a Milestone in Rare Event Detection
    BD Expands Efforts to Combat Antimicrobial Resistance with New Diagnostic Test in Europe BD Expands Efforts to Combat Antimicrobial Resistance with New Diagnostic Test in Europe
    BD Introduces New 6mm Pen Needle for Injection Pens BD Introduces New 6mm Pen Needle for Injection Pens
    Custom Electronics Become Customary Custom Electronics Become Customary
    Top 30 Global Medical Device Companies Top 30 Global Medical Device Companies
    5. Becton, Dickinson and Company 5. Becton, Dickinson and Company
    FDA Clears BD FDA Clears BD's New Immunological Diagnostic System
    BD Transforms Microbiology Urine Testing BD Transforms Microbiology Urine Testing
    FDA Clears Leukemia & Lymphoma Diagnostic Test FDA Clears Leukemia & Lymphoma Diagnostic Test

    Related Features

    • Cardiovascular | Contract Manufacturing | Diagnostics | Digital Health | Electronics | Neurological | Patient Monitoring | R&D & Design
      Customized Connections: A Discussion on Custom Electronics

      Customized Connections: A Discussion on Custom Electronics

      Demand for more complex, traceable, integrated solutions are driving innovation in the fast-changing medical electronics market.
      Michael Barbella, Managing Editor 09.09.19

    • Diagnostics | Materials
      Care Points: The Current State of Point of Care Diagnostics

      Care Points: The Current State of Point of Care Diagnostics

      Speed, convenience, and cost are driving innovation in the global point-of-care market.
      Michael Barbella, Managing Editor 06.13.19

    • Cardiovascular | Contract Manufacturing | Diagnostics | Molding | Surgical
      Once or Again? Single-Use Products Are Gaining Attention

      Once or Again? Single-Use Products Are Gaining Attention

      Bolstered by recent study findings and their infection control prowess, the single-use device market is primed for growth.
      Michael Barbella, Managing Editor 04.03.19


    • Diagnostics | Surgical
      Past Dues: Medtech

      Past Dues: Medtech's 2018 Year in Review

      The industry confronted old ghosts in 2018 as it defended itself against a documentary and crammed for regulatory changes.
      Michael Barbella, Managing Editor 11.26.18

    • Diagnostics | Digital Health | Patient Monitoring
      Home Field Advantage: Examining Home Diagnostics for Chronic Disease

      Home Field Advantage: Examining Home Diagnostics for Chronic Disease

      Diagnostic and monitoring devices designed for the home enable patients to be more proactively involved in their own health.
      Sam Brusco, Associate Editor 06.04.18

    • Cardiovascular | Diagnostics | Digital Health | Neurological | Patient Monitoring | Surgical
      Top 30 Global Medical Device Companies

      Top 30 Global Medical Device Companies

      In this year's Top 30 company reports, a number of themes seem to be shared within the mission of each company.
      Sean Fenske, Editor; Michael Barbella, Managing Editor; Sam Brusco, Associate Editor 07.27.17


    • Diagnostics | Digital Health
      House Calls

      House Calls

      An increase in chronic conditions and the ‘consumerization’ of diagnostic devices bodes well for at-home testing market.
      Michael Barbella, Managing Editor 06.06.17

    • Diagnostics | Digital Health | Electronics | Patient Monitoring
      Closing the Loop on Diabetes Care

      Closing the Loop on Diabetes Care

      Digital health technologies personalize diabetes management, easing the burden on patients and the healthcare system.
      Sam Brusco, Associate Editor 04.03.17

    • Diagnostics | Digital Health | Electronics | Patient Monitoring | Software & IT
      Software’s Coming of Age

      Software’s Coming of Age

      Successful software integration is the key to reaching higher quality and lower costs.
      Mark Crawford, Contributing Writer 03.07.17



    Trending
    • Senseonics Forges Strategic Collaboration With Ascensia Diabetes Care
    • Portable, Home-Use Device Quickly Measures Inflammation Levels
    • Henry Schein Buys Majority Interest In Prism Medical Products
    • Top 10 Trends In The Medical Device And Equipment Industry
    • Masimo Earns CE Mark For New Fingertip Pulse Oximeter
    Breaking News
    • Spectrum Solutions Collaborates with UCLA School of Dentistry
    • Kwivik Therapeutics, EirMed Partner to Accelerate Product Commercialization
    • Europe Marks its First Successful Remote Robotic-Assisted Coronary Angioplasty
    • Twist on Heart Valve Design Boosts Blood Flow, Prevents Clots
    • FDA Clears 3D Acellular Dermal Matrix
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Pharmaceutical Focus: A Look at Combination Products
    • The Printed World: Additive Manufacturing in Medtech
    • The Lost Year: 2020 Year in Review
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    PepsiCo and Beyond Meat Partner to Develop Plant-Based Protein
    New Study on Sage Extract Formula Suggests Memory Enhancement
    Omega-3s Evidenced to Reduce Low-Grade Inflammation in Elderly Men
    Coatings World

    Latest Breaking News From Coatings World

    Mayzo Makes 2 Appointments
    Mississippi Lime Company Announces New Director of Safety
    IFS Coatings Launches IFS Puroplaz PE20 Texture
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Spectrum Solutions Collaborates with UCLA School of Dentistry
    Kwivik Therapeutics, EirMed Partner to Accelerate Product Commercialization
    Europe Marks its First Successful Remote Robotic-Assisted Coronary Angioplasty
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Lilly, Vir, GSK Partner to Evaluate COVID Combo Therapies
    Novartis Invests in Credence MedSystems
    Ajinomoto Bio-Pharma, Humanigen Expand Manufacturing Agreement
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty to Shut Down Manufacturing Site in Cologne, Germany
    L’Occitane Files for Bankruptcy in U.S.
    Bésame Cosmetics Collaborates with Disney on Mary Poppins Collection
    Happi

    Latest Breaking News From Happi

    CLT Introduces Private Label Solid Air Freshener Cones
    The Florida Sunscreen Symposium Is Back!
    TFF Opens Nominations for 2021 Awards
    Ink World

    Latest Breaking News From Ink World

    Epson Partner Creates Label Applicators for Pharmaceutical Products
    Smurfit Kappa Sets New Sustainability Targets with Better Planet 2050
    Georgia-Pacific Acquires 3rd HP PageWide Corrugated Press to Expand Hummingbird Digital Printing
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex acquires MDV Group
    Fix-A-Form eyes global expansion
    McCracken Label installs Fujifilm water-wash plate system
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Nice-Pak Receives EPA Approval for Disinfecting Wipes
    Rockline to Invest $18 Million in Arkansas
    Essity’s Sales Negatively Impacted by Covid-19 Pandemic
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ChoiceSpine's Tiger Shark Cervical Spacer Earns Additional 510(k)
    FDA Green Lights Inspired Spine's Trident SI Joint Screw System
    FDA Clears Method to Extract Bone Measurements From X-Rays
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Osram Sees Jump in Profits in Preliminary 2020 Report
    LG Display Reports 4Q 2020 Results
    Xerox Releases 4Q, Full Year Results

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login